U

UroGen Pharma, Inc

Develops RTGel-based drug delivery for uro-oncology

Field Reimbursement Manager

Customer SuccessConfirmed live in the last 24 hours
Full-timeIllinois, USA$165k - $175k /yr

About the Job

Requirements

  • A bachelor's degree in a related field is required.
  • A minimum of 4 years of pharmaceutical, biotech, or medical device experience is required.
  • A minimum of 2 years of reimbursement experience is required.
  • Strong written, verbal, and interpersonal skills are required.
  • Ability to communicate cross-functionally and within the region to share results, assist in training, and develop best practices.
  • Ability to travel with overnight stays is required.
  • A valid driver's license is required.

Responsibilities

  • Ensure target accounts understand all applicable billing and coding requirements associated with UroGen products.
  • Develop and leverage relationships with key customers in target accounts.
  • Understand billing and coding responsibilities within target accounts, including urology clinics, ambulatory surgery centers, and hospitals.
  • Answer reimbursement questions for each account.
  • Understand all applicable reimbursement regulations for Medicaid, Medicare, and commercial payers.
  • Partner effectively with other members of the account team to ensure the best possible outcome for the patient and the account.
  • Translate strategies into actionable plans for each account.
  • Demonstrate expertise in the disease state, the product, the surgical process, and the reimbursement process.
  • Organize and complete administrative responsibilities efficiently and on time, including call reporting, expense reporting, communication, and account documentation.
  • Understand the opportunities unique to the geography.

Desired Qualifications

  • Two years of hospital or large-account experience is preferred.
  • Two years of urology experience is preferred.

About the Company

UroGen Pharma, Inc

Develops RTGel-based drug delivery for uro-oncology

UroGen Pharma develops RTGel-based drug-delivery therapies for urothelial and specialty cancers, commercializing products like Jelmyto and ZUSDURI and advancing a pipeline that includes UGN-102, UGN-103, UGN-104, and UGN-301. Its RTGel platform is liquid at cool temperatures and gels at body temperature, allowing chemotherapy to stay at the treatment site longer for local, sustained exposure. The company differentiates itself by delivering established chemotherapy directly to the disease site to reduce systemic exposure and by building a multi-product portfolio focused on urothelial cancers. Its goal is to improve local treatment outcomes and grow a diversified, globally commercial portfolio through ongoing clinical development and partnerships.

Company size
201-500
Company stage
IPO
Headquarters
Princeton, NJ
Founded
2004

Recently Posted Jobs

Explore more opportunities at UroGen Pharma, Inc

See more jobs